Abramson, V., Linden, H. M., Crew, K., Mortimer, J., Alidzanovic, J., Nangia, J., Layman, R., Vranjes, Z. J., Andric, Z., Milovic-Kovacevic, M., Trifunovic, J., Karchmit, Y., Suarez, J., Suster, M., Ptaszynski, M., & Chalasani, P. (2021). 565TiP A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2- breast cancer. Annals of Oncology, 32, S619. https://doi.org/10.1016/j.annonc.2021.08.1087
Subjects:
Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer
(OpenAlex Topic)
HER2 Signaling in Breast Cancer Treatment
(OpenAlex Topic)
Chemotherapy-Induced Peripheral Neuropathy in Cancer Treatment
(OpenAlex Topic)
Publication Type:
Article
Unique ID:
10.1016/j.annonc.2021.08.1087
Journal:
Publication Date:
Data Source:
OpenAlex
Source Link: